The correlation between liver enzymes and lipid profile in T2D patients in the Yemeni population has been evaluated. This is a case-control study comprising 142 T2D patients and 142 healthy control subjects were carried out at the outpatient clinics of Ibn-Sina hospital, Mukalla, during the period from January to May 2020. Serum fasting blood glucose (FBG), total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (GGT) were analyzed using the Cobas Integra Plus 400 autoanalyzer. Also, anthropometric and blood pressure measurements were taken from each participant. Independent sample T-test and Pearson correlation coefficient were used. T2D patients had significantly higher FBG (P ≤ 0.0001), total cholesterol (P ≤ 0.0001), LDL-C (P ≤ 0.0001), and GGT (P ≤ 0.0001) while HDL-C was significantly lower in T2D patients (P = 0.021). In correlation analysis, serum GGT was positively associated with FBG (r = 0.216; P ≤ 0.0001), total cholesterol (r = 0.196; P = 0.0001), triglyceride (r = 0.123; P = 0.038), and LDL-C (r = 0.209; P ≤ 0.0001). Also, serum ALT was positively associated with FBG (r = 0.145, P = 0.014) and triglyceride (r = 0.172, P = 0.004). In conclusion, higher levels of ALT and GGT are used as the predictive biomarkers for NAFLD in T2D patients with hyperlipidemia. Thus, routine screening of liver enzymes and lipid profile in T2D patients is recommended for the early detection of liver abnormalities and diminish diabetes complications.
References
[1]
World Health Organization (1999) Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part 1, Diagnosis and Classification of Diabetes Mellitus. World Health Organization, Geneva. https://apps.who.int/iris/handle/10665/66040
[2]
Al-Jameil, N., Khan, F. A., Arjumand, S., Khan, M.F. and Tabassum, H. (2014) Associated Liver Enzymes with Hyperlipidemic Profile in Type 2 Diabetes Patients. International Journal of Clinical and Experimental Pathology, 7, 4345-4349.
[3]
Hanley, A.J., Williams K., Festa, A., Wagenknecht, L.E., D’Agostino, Jr., R.B., Kempf, J., et al. (2004) Elevations in Marker of Liver Injury and Risk of Type 2 Diabetes—The Insulin Resistance Atherosclerosis Study. Diabetes, 53, 2623-2632. https://doi.org/10.2337/diabetes.53.10.2623
[4]
Gavin, N. and Levinthal, A.S.T. (1999) Liver Disease and Diabetes Mellitus. Clinical Diabetes, 17, No. 2.
[5]
Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., et al. (2016) Nonalcoholic Fatty Liver Disease Is Associated with an Almost Twofold Increased Risk of Incident Type 2 Diabetes and Metabolic Syndrome. Evidence from a Systematic Review and Meta-Analysis. Journal of Gastroenterology and Hepatology, 31, 936-944. https://doi.org/10.1111/jgh.13264
[6]
Giannini, E.G., Testa, R. and Savarino, V. (2005) Liver Enzyme Alteration: A Guide for Clinicians. Canadian Medical Association Journal, 172, 367-379. https://doi.org/10.1503/cmaj.1040752
[7]
Hanigan, M.H. and Frierson Jr., H.F. (1996) Immunohistochemical Detection of Gamma-Glutamyl Transpeptidase in Normal Human Tissue. Journal of Histochemistry & Cytochemistry, 44, 1101-11108. https://doi.org/10.1177/44.10.8813074
[8]
Turgut, O. and Tandogan, I. (2011) Gamma-Glutamyltransferase to determine Cardiovascular Risk: Shifting the Paradigm Forward. Journal of Atherosclerosis and Thrombosis, 18, 177-181.
[9]
Lee, D.H. and Jacobs Jr., D.R. (2005) Association between Serum Gamma-Glutamyl transferase and C-Reactive Protein. Atherosclerosis, 178, 327-330. https://doi.org/10.1016/j.atherosclerosis.2004.08.027
[10]
Wang, Y., Koh, W., Yuan, J. and Pan, A. (2016) Association between Liver Enzymes and Incident Type 2 Diabetes in Singapore Chinese Men and Women. BMJ Open Diabetes Research and Care, 4, e000296. https://doi.org/10.1136/bmjdrc-2016-000296
[11]
Ginsberg, H.N., Zhang, Y.L. and Hernandez-Ono, A. (2006) Metabolic Syndrome: Focus on Dyslipidemia. Obesity, 14, 41S-49S. https://doi.org/10.1038/oby.2006.281
[12]
Balaji, A.S., Suhas, B.J., Ashok, M.A. and Mangesh, T. (2013) Serum Alanine Transaminases and Lipid Profile in Type 2 Diabetes Mellitus Indian Patient. Journal of Research in Diabetes, 2013, Article ID: 613176. https://doi.org/10.5171/2013.613176
[13]
Rajeswari, S., Kumar, A., Gandhi, M. and Swaminathan, S. (2014) Association between Lipid Profile and Liver Function Tests in Diabetic Patients. Indian Journal of Pure & Applied Biosciences, 2, 26-31.
[14]
American Diabetes Association (2016) Standards of Medical Care in Diabetes-2016. Diabetes Care, 39, S4-S5. https://doi.org/10.2337/dc16-S003
[15]
World Health Organization (1995) Physical Status: The Use and Interpretation of Anthropometry (1995) Report of WHO Expert Committee. WHO Technical Report Series, No. 854, World Health Organization, Geneva, 321-344. https://apps.who.int/iris/handle/10665/37003.
[16]
Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr., J.L., et al. (2003) Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252. https://doi.org/10.1161/01.HYP.0000107251.49515.c2
[17]
Kwo, P.Y., Cohen, S.M. and Lim, J.K. (2017) ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. American Journal of Gastroenterology, 112, 18-35. https://doi.org/10.1038/ajg.2016.517
[18]
Friedewald, W.T., Levy, R.I. and Fredrickson, D.S. (1972) Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, without Use of the Preparative Ultracentrifuge. Clinical Chemistry, 18, 499-502. https://doi.org/10.1093/clinchem/18.6.499
[19]
Nwarfor, A. and Owhoji, A. (2001) The Prevalence of Diabetes Mellitus in Port-Harcourt Correlates with the Socio-Economic Status. Journal of Applied Sciences and Environmental Management, 5, 75-77.
[20]
Jain, H.R., Shetty, V., Singh, G.S. and Shetty, S. (2016) A Study of Lipid Profile in Diabetes Mellitus. International Journal of Scientific Study, 4, 56-61.
[21]
Han, N., Soe, H.K. and Htet, A. (2012) Determinants of Abnormal Liver Function Tests in Diabetes Patients in Myanmar. International Journal of Diabetes Research, 1, 36-41. https://doi.org/10.5923/j.diabetes.20120103.02
[22]
Belay, Z., Daniel, S., Tedla, K. and Gnanasekaran, N. (2014) Impairment of Liver Function Tests and Lipid Profiles in Type 2 Diabetic Patients Treated at the Diabetic Center in Tikur Anbessa Specialized Teaching Hospital (Tasth), Addis Ababa, Ethiopia. Journal of Diabetes and Metabolism, 5, Article No. 11. https://doi.org/10.4172/2155-6156.1000454
[23]
Adeniran, S.A., Dolapo, P.O., Oluwole, A.B., Adeola ‘Niran-Atiba, T., Jimoh, A.K. and Adepeju, A.A. (2013) Liver Enzymes and Lipid Profile among Type 2 Diabetic Patients in Osogbo, Nigeria. Greener Journal of Medical Sciences, 3, 174-178. https://doi.org/10.15580/GJMS.2013.5.011313373
[24]
Tolman, K.G., Fonseca, V., Dalpiaz, A. and Tan, M.H. (2007) Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients with Diabetes and Liver Disease. Diabetes Care, 30, 734-743. https://doi.org/10.2337/dc06-1539
[25]
Nannipieri, M., Gonzales, C., Baldi, S., Posadas, R., Williams, K., Haffner, S.M., et al. (2005) Liver Enzymes, the Metabolic Syndrome, and Incident Diabetes: The Mexico City Diabetes Study. Diabetes Care, 28, 1757-1762. https://doi.org/10.2337/diacare.28.7.1757
[26]
Cho, N.H., Jang, H.C., Choi, S.H., Kim, H.R., Lee, H.K., Chan, J.C.N., et al. (2007) Abnormal Liver Function Test Predicts Type 2 Diabetes: A Community-Based Prospective Study. Diabetes Care, 30, 2566-2568. https://doi.org/10.2337/dc07-0106
[27]
Tolman, K.G., Fonseca, V., Tan, M.H. and Dalpiaz, A. (2004) Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus. Annals of Internal Medicine, 141, 946-956. https://doi.org/10.7326/0003-4819-141-12-200412210-00011
[28]
Chatila, R. and West, A.B. (1996) Hepatomegaly and Abnormal Liver Tests Due to Glycogenosis in Adults with Diabetes. Medicine, 75, 327-333. https://doi.org/10.1097/00005792-199611000-00003
[29]
Sharma, M., Vikram, N.K., Misra, A., Bhatt, S.P., Tarique, M., Parray, H.A., et al. (2013) Assessment of 11-Beta Hydroxysteroid Dehydrogenase (11-betaHSD1) 4478T>G and Tumor Necrosis Factor-Alpha (TNF-Alpha)-308>A Polymorphisms with Obesity and Insulin Resistance in Asian Indians in North India. Molecular Biology Reports, 40, 6261-6270. https://doi.org/10.1007/s11033-013-2738-5
[30]
Chen, Z., Yu, R., Xiong, Y., Du, F. and Zhu, S. (2017) A Vicious Circle between Insulin Resistance and inflammation in Nonalcoholic Fatty Liver Disease. Lipids in Health and Disease, 16, Article No. 203. https://doi.org/10.1186/s12944-017-0572-9
[31]
Lee, D.H., Silventonein, K., Jacobs, D.R., Jousilahti, P. and Tuomileto, J. (2014) Gamma-Glutamyltransferase, Obesity and the Risk of Type 2 Diabetes Observational Cohort Study among 20,158 Middle Aged Men and Women. The Journal of Clinical Endocrinology & Metabolism, 89, 5410-5414. https://doi.org/10.1210/jc.2004-0505
[32]
Lee, D.H., Ha, M.H., Kim, J.H., Christiani, D.C., Gross, M.D., Steffes, M., et al. (2003) Gamma-Glutamyltransferase and Diabetes—A Four Year Follow up Study. Diabetologia, 46, 359-364. https://doi.org/10.1007/s00125-003-1036-5
[33]
Nakanishi, N., Suzuki, K. and Tatara, K. (2004) Serum Gamma-Glutamyltransferase and Risk of Metabolic Syndrome and Type 2 Diabetes in Middle Aged Japanese Men. Diabetes Care, 27, 1427-1432. https://doi.org/10.2337/diacare.27.6.1427
[34]
Lee, D.H., Jacobs, D.R., Gross, M., Kiefe, C.I., Roseman, J., Lewis, C.E., et al. (2003) Gamma-Glutamyltransferase Is a Predictor of Incident Diabetes and Hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clinical Chemistry, 49, 1358-1366. https://doi.org/10.1373/49.8.1358
[35]
Sakuta, H., Suzuki, T., Yasuda, H. and Ito, T. (2005) Gamma-Glutamyl Transferase and Airflow Obstruction in Middle-Aged Men. European Journal of Internal Medicine, 16, 348-351. https://doi.org/10.1016/j.ejim.2005.06.005
[36]
Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Bugianesi, E., Lenzi, M., et al. (2001) Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome. Diabetes, 50, 1844-1850. https://doi.org/10.2337/diabetes.50.8.1844
[37]
Ahn, H.R., Nam, H.S., Park, K.S., Park, K.-S., Lee, Y.-H., Jeong, S.-K., et al. (2014) The Association between Liver Enzymes and Risk of Type 2 Diabetes: The Namwon Study. Diabetology & Metabolic Syndrome, 6, Article No. 14. https://doi.org/10.1186/1758-5996-6-14
[38]
Vozarova, B., Stefan, N., Lindsay, R.S., Saremi, A., Pratley, R.E., Bogardus, C., et al. (2002) High Alanine Aminotransferase Is Associated with Decreased Hepatic Insulin Sensitivity and Predicts the Development of Type 2 Diabetes. Diabetes, 51, 1889-1895. https://doi.org/10.2337/diabetes.51.6.1889
[39]
Clark, J.M. and Diehl, A.M. (2003) Nonalcoholic Fatty Liver Disease: An Underrecognized Cause of Cryptogenic Cirrhosis. JAMA, 290, 3000-3004. https://doi.org/10.1001/jama.289.22.3000
[40]
Clark, J.M., Brancati, F.L. and Diehl, A.M. (2003) The Prevalence and Etiology of Elevated Aminotransferase Levels in the United States. American Journal of Gastroenterology, 98, 960-967. https://doi.org/10.1111/j.1572-0241.2003.07486.x
